Key result
Subpotent clopidogrel oral liquids trigger recalls and patient outreach due to low drug levels.
Why the study?
Batches of a brand of clopidogrel oral suspension and oral solution were recalled because they contained less than the labelled amount of drug.
A class two recall was issued by the MHRA for specific batches of clopidogrel oral suspension and solution due to containing less than the labelled amount of active drug, requiring pharmacists to contact affected patients.
Patients on recalled subpotent clopidogrel require immediate switch to avoid underdosing; leaves open outcome impact of this regulatory action.
Pharmacists are being asked to contact all patients taking a brand of clopidogrel oral suspension and oral solution, following a product recall owing to batches containing less than the labelled amount of drug. In a class two recall notice published on 26 October 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) said that manufacturer […]
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question. Clopidogrel oral suspension and solution batches were recalled after containing less than the labelled drug amount, prompting pharmacists to contact affected patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: